Parad+TM

Protecting patients for over 20 years.
World's first dual-chamber discrimination algorithm.

Healthcare Professionals Cardiac Rhythm Management Pacemakers Parad+

Parad+TM

Parad+TM is a dual-chamber discrimination algorithm which discriminates ventricular tachycardia from supraventricular tachycardia or sinus tachycardia.

It has been designed with the typical ECG characteristics of the different tachycardia rhythms.
By featuring AF DetectTM, Parad+TM is the only discriminator to include beat-to-beat R-R long cycle search to distinguish stable, rapidly conducted AF from VT.

  • Low inappropriate shock rate
  • Best in class 99% specificity1
  • Immediate protection with Parad+TM out-of-the-box settings*

*Not applicable to US devices

20201009 Hospital campaign brief webpage

How it works

Parad+TM discriminates ventricular tachycardia from supraventricular or sinus tachycardia based on the following criteria:

  1. RR stability: stable or unstable?
  2. PR association: associated or dissociated? If dissociated, long cycle search is triggered (AF DetectTM).
  3. Level of PR association: N:1 or 1:1?
  4. Acceleration: sudden or gradual?
  5. Origin of acceleration: atrial or ventricular?
Graph parad plus en 2020

Performance

Parad+TM is the best-in-class arrhythmia discrimination algorithm with 99% specifity.1
The OPTION study demonstrated a low inappropriate shock rate at only 2.6% at one year with conventional settings*.2

*Conventional settings:
VT zone [170-200] bpm, 12 cycles persistence
VF zone > 200 bpm, 6 cycles persistence

Click here to download the study
Parad2

Related products: PlatiniumTM; PlatiniumTM 4LV SonRTM CRT-D; PlatiniumTM 4LV CRT-D

Availability of select products and their functions varies by country. Please check with your representative for further information.


REFERENCES

  1. Hintringer F, et al. Comparison of the Specificity of Implantable Dual Chamber Defibrillator Detection Algorithms. Pacing Clin Electrophysiol. 2004;27:976–82.
  2. Kolb C, et al. Reduced Risk for Inappropriate Implantable Cardioverter-Defibrillator Shocks With Dual-Chamber Therapy Compared With Single-Chamber Therapy.Results of the randomized Option study. JACC Heart Failure 2014;2:611–19.